Philip Morris International Inc
Change company Symbol lookup
Select an option...
PM Philip Morris International Inc
BHR Braemar Hotels & Resorts Inc
ESALY Eisai Co Ltd
CNX CNX Resources Corp
WW WW International Inc
IBM International Business Machines Corp
NEP Nextera Energy Partners LP
TMP Tompkins Financial Corp
MFM MFS Municipal Income Trust
HMNKF HMS Networks AB
Go

Consumer Staples : Tobacco | Large Cap Value
Company profile

Philip Morris International Inc. is a holding company. The Company is engaged in the manufacture and sale of cigarettes, other tobacco products and other nicotine-containing products in markets outside of the United States. Its segments include European Union (EU); Eastern Europe, Middle East & Africa (EEMA); Asia, and Latin America & Canada. The Company's portfolio of international and local brands is led by Marlboro. Its mid-price brands are L&M, Lark, Merit, Muratti and Philip Morris. Its other international brands include Bond Street, Chesterfield, Next and Red & White. The Company also owns various local cigarette brands, such as Dji Sam Soe, Sampoerna and U Mild in Indonesia; Champion, Fortune and Jackpot in the Philippines; Apollo-Soyuz and Optima in Russia; Morven Gold in Pakistan; Boston in Colombia; Belmont, Canadian Classics and Number 7 in Canada; f6 in Germany; Delicados in Mexico; Assos in Greece, and Petra in the Czech Republic and Slovakia.

Closing Price
$74.45
Day's Change
-0.41 (-0.55%)
Bid
--
Ask
--
B/A Size
--
Day's High
75.37
Day's Low
74.31
Volume
(Below Average)
Volume:
3,823,431

10-day average volume:
4,637,869
3,823,431

UPDATE: There are seven coronavirus vaccine candidates being tested in the U.S. -- here's where they stand

6:36 am ET September 10, 2020 (MarketWatch)
Print

By Jaimy Lee

At least three of the still investigational vaccines have moved into Phase 3 clinical trials

The race to develop a safe and effective COVID-19 vaccine is well under way, setting the stage to bring to market the fastest vaccine in history.

There are dozens of coronavirus vaccines in development, primarily in the preclinical phase when they are tested on animals. In the U.S., there are seven vaccine candidates that have moved into clinical trials with human participants, including three that have moved into the crucial Phase 3 development phase.

The first and second phases of clinical studies are primarily conducted to test for safety, while the third and final stage is used to determine whether vaccines are efficacious and can prevent infection among participants. At that point, the vaccine makers will decide when to pursue an emergency-use authorization from the Food and Drug Administration and/or a full approval. The majority of the vaccines in development have received funding from the U.S. government, either to help support clinical development or pay for manufacturing and distribution of the vaccines as part of the Trump administration's "Operation Warp Speed" program.

MarketWatch will update this tally as the vaccines move through development.

Vaccines in Phase 3 trials in the U.S. (cited in alphabetical order, by company name):

-- AstraZeneca (AZN.LN) (AZN.LN), in partnership with the University of Oxford

Year-to-date stock performance: Up 7.8%.

Name: AZD1222.

Type: Vector-based.

Phase 1/2: Data from the Phase 1/2 trial, which is being conducted in the U.K., was published July 20 in the Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext). It reported (http://www.marketwatch.com/story/astrazenecas-stock-fall-3-as-results-from-early-stage-study-on-coronavirus-vaccine-are-published-2020-07-20) neutralizing antibody responses in 91% of 35 patients when using one test and 100% of 35 patients when using a different test.

Phase 3: This trial, which will be held in the U.S., is expected to enroll up to 30,000 participants. (Late-stage studies are also being conducted in Brazil, South Africa and the U.K.) Data are expected by the end of the year. However, trials were halted (http://www.marketwatch.com/story/astrazeneca-stock-falls-as-drugmaker-pauses-vaccine-trial-after-volunteers-unexplained-illness-2020-09-09) in early September over concerns about a serious adverse event.

Clinical development and manufacturing funding from the U.S. government: up to $1.2 billion.

U.S. dose promise: 300 million doses.

Dosing: 2 doses.

-- BioNTech (BNTX) and Pfizer Inc. (PFE)

Year-to-date stock performances: BioNTech, up 75%; Pfizer, down 8.3%.

Name: BNT162b2.

Type: mRNA.

Phase 1: The companies published preliminary data on July 1 for BNT162b1 as a preprint (https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1). (https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1) They said then (http://www.marketwatch.com/story/after-months-of-speculation-investors-get-excited-about-pfizer-biontechs-coronavirus-vaccine-candidate-2020-07-01) that 24 participants in the study who received two doses of the lower-dose vaccine developed neutralizing antibodies. A second preprint (https://www.medrxiv.org/content/10.1101/2020.08.17.20176651v2) was published on Aug. 28 for BNT162b2 that found this candidate produced similar levels of antibodies but participants reported fewer reactions.

Phase 2/3: (https://clinicaltrials.gov/ct2/show/NCT04368728) This trial is expected to focus on BNT162b2. It is expected to enroll up to 30,000 participants in Argentina, Brazil and the U.S.

Manufacturing funding from the U.S. government: $1.95 billion.

U.S. dose promise: 100 million doses, with option to buy up to 500 million more doses.

Dosing: 2 doses.

-- Moderna Inc. (MRNA)

Year-to-date stock performance: Up 187.8%.

Name: mRNA-1273.

Type: mRNA.

Phase 1 (https://clinicaltrials.gov/ct2/show/NCT04283461): Preliminary data (http://www.marketwatch.com/story/modernas-stock-soars-on-compelling-early-data-for-its-coronavirus-vaccine-candidate-2020-05-18) were released May 18; more detailed data (http://www.marketwatch.com/story/modernas-stock-extends-rally-as-experts-look-to-the-coming-phase-3-study-of-the-coronavirus-vaccine-candidate-2020-07-15) published July 14 in the New England Journal of Medicine (https://www.nejm.org/doi/full/10.1056/NEJMoa2022483) (https://www.nejm.org/doi/full/10.1056/NEJMoa2022483). Moderna's vaccine candidate elicited neutralizing antibodies in all 45 participants in this trial, which was conducted in the U.S. in partnership with the National Institute of Allergy and Infectious Diseases.

Phase 2a (https://clinicaltrials.gov/ct2/show/NCT04405076): This study closed enrollment of 600 participants on July 8. This trial is also focused on the U.S.

Phase 3 (https://clinicaltrials.gov/ct2/show/NCT04470427): This study is expected to complete enrollment of up to 30,000 people some time in September.

R&D funding from BARDA: $955 million.

Supply funding from the U.S. government: Up to $1.525 billion.

U.S. dose promise: 100 million, with option to acquire up 400 million additional doses.

Dosing: 2 doses.

Vaccines in Phase 1 and 2 trials in the U.S. (cited in alphabetical order, by company name):

-- Inovio Pharmaceuticals Inc. (INO)

Year-to-date stock performance: Up 191.2%.

Name: INO-4800.

Type: DNA.

Phase 1 (https://clinicaltrials.gov/ct2/show/NCT04336410?term=INO-4800&draw=2&rank=1): The company released some preliminary data (http://www.marketwatch.com/story/inovios-stock-falls-as-it-discloses-early-stage-data-for-its-covid-19-vaccine-candidate-2020-06-30) on June; it has not yet shared the full data but has submitted the results for publication in a peer-reviewed medical journal. The trial is being conducted in the U.S.

Phase 2/3: Inovio said on Sept. 8 that it plans to launch this phase of the study in September, if it is given the go-ahead by the FDA.

U.S. government funding: It received $71 million (http://www.marketwatch.com/story/inovio-shares-jump-on-government-funding-for-vaccine-device-2020-06-23) from the Department of Defense to make and buy the devices that will be used to dispense the company's vaccine if it is authorized or approved.

-- Johnson & Johnson (JNJ)

Year-to-date stock performance: Up 1.2%.

Name: Ad26. COV2. S.

Type: Vector-based.

Phase 1/2a (https://clinicaltrials.gov/ct2/show/NCT04436276): The study began (http://www.marketwatch.com/story/johnson-johnson-starts-trial-of-covid-19-vaccine-after-producing-immune-response-in-primates-2020-07-30) in the second half of July, with a goal of enrolling 1,045 adults in Belgium and the U.S.

Phase 3: It plans to launch this trial in September.

R&D funding from BARDA: $456 million

U.S. government funding for manufacturing and delivery:More than $1 billion (http://www.marketwatch.com/story/jj-to-receive-1-billion-in-us-funding-to-make-100-million-doses-of-its-covid-19-vaccine-2020-08-05) (from BARDA and the Department of Defense).

U.S. dose promise: 100 million doses, with option to buy up to 200 million additional doses.

-- Novavax Inc. (NVAX)

Year-to-date stock performance: Up 2,167.6%.

Name: NVX-CoV2373.

Type: Protein subunit.

Phase 1: (https://clinicaltrials.gov/ct2/show/NCT04368988) Preliminary data from a trial conducted in Australia were published Sept. 2 in the New England Journal of Medicine (https://www.nejm.org/doi/full/10.1056/NEJMoa2026920?query=featured_coronavirus).

Phase 1/2: The second phase of the Phase 1/2 trial started in August and will be conducted in Australia and the U.S.

Phase 3: TBD.

Clinical development and manufacturing funding from the U.S. government:$1.6 billion (http://www.marketwatch.com/story/novavax-shares-soar-38-premarket-on-news-of-16-billion-in-funding-for-covid-19-vaccine-candidate-2020-07-07).

U.S. dose promise: 100 million doses.

-- Sanofi (SAN.FR) (SAN.FR), in combination with GlaxoSmithKline's (GSK.LN) (GSK.LN)adjuvant technology

Year-to-date stock performance: Up 0.6%.

Name: TBD.

Type: Protein-based.

Phase 1/2 study: The trial was initiated Sept. 3 (http://www.marketwatch.com/story/sanofi-gsks-coronavirus-vaccine-candidate-enters-clinical-trials-2020-09-03), with a goal of enrolling 440 adults in the U.S. Results are expected in December.

Phase 3: This study is expected to launch by the "end of 2020."

Clinical development and manufacturing funding from the U.S. government: Up to $2.1 billion.

U.S. dose promise: Up to 100 million doses, with option to buy up to 500 million doses.

Sources: Company websites, federal data, the World Health Organization, RBC Capital Markets.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

September 10, 2020 06:36 ET (10:36 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.